keyword
https://read.qxmd.com/read/38527618/probing-the-mechanisms-underlying-the-transport-of-the-vinca-alkaloids-by-p-glycoprotein
#21
JOURNAL ARTICLE
Gershon A K Mensah, Katherine G Schaefer, Arthur G Roberts, Gavin M King, Michael G Bartlett
The efficacy of many cancer drugs is hindered by P-glycoprotein (Pgp), a cellular pump that removes drugs from cells. To improve chemotherapy, drugs capable of evading Pgp must be developed. Despite similarities in structure, vinca alkaloids (VAs) show disparate Pgp-mediated efflux ratios. ATPase activity and binding affinity studies show at least two binding sites for the VAs: high- and low-affinity sites that stimulate and inhibit the ATPase activity rate, respectively. The affinity for ATP from the ATPase kinetics curve for vinblastine (VBL) at the high-affinity site was 2- and 9-fold higher than vinorelbine (VRL) and vincristine (VCR), respectively...
March 23, 2024: Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38527420/network-meta-analysis-of-first-line-systemic-regimens-for-older-patients-with-advanced-nsclc
#22
JOURNAL ARTICLE
Andrea Luciani, Lorenzo Dottorini, Elena Battaiotto, Fausto Petrelli
Various immunotherapy treatments have received approval for the treatment of advanced non-small cell lung cancer (NSCLC), either as standalone or in conjunction with chemotherapy, contingent upon the extent of PD-L1 expression. These treatments are commonly utilized in clinical practice. However, a specific gap exists in direct comparisons of these regimens in elderly patients. The aim of this network meta-analysis (NMA) was to examine the effectiveness of PD-1/PD-L1 inhibitors, either alone or in conjunction with chemotherapy, as the initial treatment for elderly patients diagnosed with advanced NSCLC...
March 19, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38527419/hmox1-regulates-ferroptosis-via-mic14-and-its-impact-on-chemotherapy-resistance-in-small-cell-lung-cancer
#23
JOURNAL ARTICLE
Yujie Sun, Jian Zhang
This study aimed to investigate the role and molecular mechanism of heme oxygenase-1 (HMOX1) in chemotherapy resistance in small-cell lung cancer (SCLC). Employed bioinformatics, qPCR, and Western Blot to assess HMOX1 levels in SCLC versus normal tissues and its prognostic relevance. CCK-8, flow cytometry, and thiobarbituric acid assays determined HMOX1's impact on SCLC chemosensitivity, ferroptosis markers, lipid peroxidation, and mic14's role in chemoresistance. In the GSE40275 and GSE60052 cohorts, HMOX1 expression was downregulated in SCLC tissues compared to normal tissues...
March 11, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38527329/early-dose-reduction-of-osimertinib-in-advanced-egfr-mutated-non-small-cell-lung-cancer
#24
JOURNAL ARTICLE
Marion Ferreira, Matthew I Ebia, Karen L Reckamp
Osimertinib has become the standard of care for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). In order to prevent or treat toxicity, the osimertinib dose may be reduced. However, data regarding the impact of dose reduction during treatment are limited. We aimed to compare the efficacy of osimertinib early dose reduction during the first 3 months of treatment with late dose reduction in EGFR-mutated advanced NSCLC. This retrospective study included patients with EGFR-mutated advanced NSCLC who received osimertinib...
March 22, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38527281/brigatinib-combined-with-cetuximab-in-the-fifth-line-treatment-of-non-small-cell-lung-cancer-with-egfr-p-c797s-mutation-in-critically-ill-patients-a-report-of-two-cases-and-literature-review
#25
JOURNAL ARTICLE
Juanjuan Liu, Hongtao Lei, Ding Zhang, Ning Zhang
For critically ill patients with non-small cell lung cancer (NSCLC) in need of life-saving treatment, there is currently no reported evidence regarding the use of medication specifically targeting epidermal growth factor receptor (EGFR) p.C797S mutation, which is known to cause resistance to third-generation tyrosine kinase inhibitors (TKIs). Our report aims to investigate and explore treatment strategies to overcome resistance associated with EGFR p.C797S mutation in order to provide potential therapeutic options for these patients...
March 15, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38527277/tislelizumab-plus-chemotherapy-is-an-optimal-option-for-second-line-treatment-for-advanced-gastroesophageal-junction-adenocarcinoma
#26
JOURNAL ARTICLE
Ping Yang, Tao Pan, Ming-Kun Wang, Meng-Sheng Xiao, Shuang Zhang, Sha Liu
The development of programmed cell death receptor-1 and its ligand (PD-L1) have offered new treatment options for several cancers, but the clinical benefit of tislelizumab in the gastroesophageal junction (GEJ) adenocarcinoma is still murky. Thus, we aim to investigate the efficacy and safety of tislelizumab combined with chemotherapy in patients with GEJ cancer. In this study, 90 GEJ patients were retrospectively enrolled including 45 patients who received chemotherapy plus tislelizumab while 45 underwent chemotherapy only...
March 22, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38527238/bergaptol-inhibits-glioma-cell-proliferation-and-induces-apoptosis-via-stat3-bcl-2-pathway
#27
JOURNAL ARTICLE
Hao Huang, Junrong Zhang, Jianbing Wu, Chunfu Du, Bo Zheng, Zhangchao Guo, Ligang Chen, Deming Zhang, Luotong Liu
Glioblastoma (GBM) is the most common primary malignant brain tumour and lacks therapeutic options with significant effects. The aberrant activation of STAT3 is a critical factor in glioma progression via activating multiple signalling pathways that promote glioma. Among them, the antiapoptotic gene Bcl-2 could be upregulated by p-STAT3, which is an important reason for the continuous proliferation of glioma. We previously reported that bergaptol, a natural furanocoumarin widely found in citrus products, exerts antineuroinflammatory effects by inhibiting the overactivation of STAT3...
March 22, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38527223/pityriasiform-drug-eruption-associated-with-venetoclax-for-acute-myeloid-leukaemia
#28
JOURNAL ARTICLE
Timothy J Liu, Erin K McMeniman
Venetoclax is a targeted antileukaemic therapy that has emerged as the primary treatment of acute myeloid leukaemia in patients of advanced age or who would otherwise be ineligible for standard chemotherapy. Despite the documented evidence of cutaneous side effects of venetoclax, few reports have clarified presenting cutaneous features beyond the descriptors 'rash' and 'pruritus'. In this report, we describe the development of a pityriasiform drug eruption following venetoclax-based induction therapy for acute myeloid leukaemia...
March 22, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38526828/cryptocaryone-induces-apoptosis-in-human-hepatocellular-carcinoma-cells-by-inhibiting-aerobic-glycolysis-through-akt-and-c-src-signaling-pathways
#29
JOURNAL ARTICLE
Chen-Lin Yu, Yu-Wei Lai, Jih-Jung Chen, Jie-Jen Lee, Tsung-Hsien Chou, Chen-Chen Huang, Shih-Chia Liu, Guang-Wei Chen, Chung-Hsin Tsai, Shih-Wei Wang
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, with the second highest mortality rate in all cancer. Energy reprogramming is one of the hallmarks of cancer, and emerging evidence showed that targeting glycolysis is a promising strategy for HCC treatment. Cryptocaryone has been shown to display promising anti-cancer activity against numerous types of cancer. Previous study also indicated that cryptocaryone induces cytotoxicity by inhibiting glucose transport in cancer cells, but the detailed mechanism still needs to be elucidated...
December 15, 2023: Journal of Food and Drug Analysis
https://read.qxmd.com/read/38526826/isolation-of-glp-1-enhancing-indolizidine-alkaloids-from-boehmeria-formosana
#30
JOURNAL ARTICLE
Ching-Yi Lu, Zheng-Ying Huang, Meng-Chin Chen, Hui-Kang Liu, Shoei-Sheng Lee, Chia-Chuan Chang
Boehmeria formosana, with its related species, demonstrates anti-glycemic effect, inhibition of HBV production, anti-cancer activities, etc. Some indolizidine alkaloids from the same genus are bioactive but sensitive to light. To overcome this problem and obtain more phenanthroindolizidine alkaloids, isolation was performed in darkness, yielding 10 new indolizidine alkaloids and 17 known compounds. Among them, seven enhanced glucagon-like receptor 1 (GLP-1) activity at 50 mM, especially 14 and 6 (3.5- and 2...
December 15, 2023: Journal of Food and Drug Analysis
https://read.qxmd.com/read/38526738/curcumin-coating-a-novel-solution-to-mitigate-inherent-carbon-nanotube-toxicity
#31
JOURNAL ARTICLE
Samiksha Rele, Chanchal Kiran Thakur, Fatima Khan, Budhadev Baral, Vaishali Saini, Chandrabose Karthikeyan, N S Hari Narayana Moorthy, Hem Chandra Jha
Multi-walled Carbon Nanotubes (MWCNTs) are inert structures with high aspect ratios that are widely used as vehicles for targeted drug delivery in cancer and many other diseases. They are largely non-toxic in nature however, when cells are exposed to these nanotubes for prolonged durations or at high concentrations, they show certain adverse effects. These include cytotoxicity, inflammation, generation of oxidative stress, and genotoxicity among others. To combat such adverse effects, various moieties can be attached to the surface of these nanotubes...
March 25, 2024: Journal of Materials Science. Materials in Medicine
https://read.qxmd.com/read/38526702/osteopontin-promotes-tumor-growth-and-metastasis-and-gpx4-mediated-anti-lipid-peroxidation-in-triple-negative-breast-cancer-by-activating-the-pi3k-akt-mtor-pathway
#32
JOURNAL ARTICLE
Man Guo, Mengyue Liu, Weihan Li, Cao Wang, Lu Zhang, Hao Zhang
PURPOSE: Triple-negative breast cancer (TNBC) features high aggressiveness, metastasis rate, drug resistance as well as poor prognosis. Osteopontin (OPN) is a key protein in the process of osteogenesis and has emerged as a new tumor marker in recent years. METHODS: Cell viability was tested with the CCK-8 kit. Transwell and wound healing were adopted to test cell invasive and migratory abilities. Tumor sphere formation was detected by tumor sphere formation assay...
March 25, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38526562/viruses-exploit-growth-factor-mechanisms-to-achieve-augmented-pathogenicity-and-promote-tumorigenesis
#33
REVIEW
Sarvenaz Sabourirad, Evdokia Dimitriadis, Theo Mantamadiotis
Cellular homeostasis is regulated by growth factors (GFs) which orchestrate various cellular processes including proliferation, survival, differentiation, motility, inflammation and angiogenesis. Dysregulation of GFs in microbial infections and malignancies have been reported previously. Viral pathogens exemplify the exploitation of host cell GFs and their signalling pathways contributing to viral entry, virulence, and evasion of anti-viral immune responses. Viruses can also perturb cellular metabolism and the cell cycle by manipulation of GF signaling...
March 25, 2024: Archives of Microbiology
https://read.qxmd.com/read/38526354/can-duvelisib-and-eganelisib-work-for-both-cancer-and-covid-19-molecular-level-insights-from-md-simulations-and-enhanced-samplings
#34
JOURNAL ARTICLE
Saroj Kumar Panda, Shaswata Karmakar, Parth Sarthi Sen Gupta, Malay Kumar Rana
SARS-CoV-2 has caused severe illness and anxiety worldwide, evolving into more dreadful variants capable of evading the host's immunity. Cytokine storms, led by PI3Kγ, are common in cancer and SARS-CoV-2. Naturally, there is a yearning to see whether any drugs could alleviate cytokine storms for both. Upon investigation, we identified two anticancer drugs, Duvelisib and Eganelisib, that could also work against SARS-CoV-2. This report is the first to decipher their synergic therapeutic effectiveness against COVID-19 and cancer with molecular insights from atomistic simulations...
March 25, 2024: Physical Chemistry Chemical Physics: PCCP
https://read.qxmd.com/read/38525374/extensive-stage-small-cell-lung-cancer-with-cystic-brain-metastases-a-report-of-two-cases
#35
Fei Cai, Di Wu, Junling Liu, Shuxi Song, Jingyu Li, Zhendong Zheng, Long Xu
OBJECTIVE: Cystic brain metastases (BMs) are rare in small cell lung cancer (SCLC), and there are limited data on the treatment and prognosis of cystic BMs. Whole brain radiotherapy has been the mainstay for BMs since several years. Immune checkpoint inhibitors in extensive stage small cell lung cancer (ES-SCLC) have been shown to be suitable for patients who experienced better overall survival and progress-free survival and have been approved as the first-line treatment for ES-SCLC. In this report, we described two ES-SCLC patients developed cystic BMs after immunotherapy, after which the patients continued to treat the primary lesion with immune checkpoint inhibitors and the cystic BMs with radiotherapy...
2024: Cancer Management and Research
https://read.qxmd.com/read/38524877/understanding-sorafenib-induced-cardiovascular-toxicity-mechanisms-and-treatment-implications
#36
REVIEW
Jue Li, Lusha Zhang, Teng Ge, Jiping Liu, Chuan Wang, Qi Yu
Tyrosine kinase inhibitors (TKIs) have been recognized as crucial agents for treating various tumors, and one of their key targets is the intracellular site of the vascular endothelial growth factor receptor (VEGFR). While TKIs have demonstrated their effectiveness in solid tumor patients and increased life expectancy, they can also lead to adverse cardiovascular effects including hypertension, thromboembolism, cardiac ischemia, and left ventricular dysfunction. Among the TKIs, sorafenib was the first approved agent and it exerts anti-tumor effects on hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) by inhibiting angiogenesis and tumor cell proliferation through targeting VEGFR and RAF...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38524742/effectiveness-of-pd1-pd-l1-combined-with-anti-angiogenic-drugs-in-patients-with-advanced-nonsmall-cell-lung-cancer-a-systematic-review-and-meta-analysis
#37
REVIEW
Xueyu Duan, Xiaobo Liu, Ruixiang Chen, Yanjiao Pu
BACKGROUND: Protein-1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) therapy have become an important treatment approach for patients with advanced nonsmall cell lung cancer (NSCLC), but primary or secondary resistance remains a challenge for some patients. PD-1/PD-L1 combined with anti-angiogenic drugs (AAs) in NSCLC patients have potential synergistic effects, and the survival benefit may vary based on a treatment order. To investigate the efficacy of PD-1/PD-L1 combined with AAs as the treatment for patients with advanced NSCLC...
2024: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
https://read.qxmd.com/read/38524612/synthesis-characterization-and-efficacy-evaluation-of-a-ph-responsive-fe-mof-go-composite-drug-delivery-system-for-the-treating-colorectal-cancer
#38
JOURNAL ARTICLE
Jia-Jie Shen, Shi-Jiao Xue, Zhang-Hao Mei, Ting-Ting Li, Hui-Fen Li, Xue-Fei Zhuang, Lin-Mei Pan
Luteolin is a potent anti-colorectal cancer chemical. However, its effectiveness is hindered by its poor solubility in water and fat, and it is easy to degrade by gastrointestinal enzymes. In this study, a nano-composite carrier, NH2 -MIL-101(Fe)@GO (MG), based on aminated MIL-101(Fe) and graphene oxide (GO) was developed and evaluated. This carrier co-delivered luteolin and matrine, while marine was used to balance the pH for the nano-preparation. The loading capacities for luteolin and matrine were approximately 9...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38524583/improved-anti-cancer-effects-of-luteolin-zif-8-in-cervical-and-prostate-cancer-cell-lines
#39
JOURNAL ARTICLE
Linlin Ding, Hao Chen, Guoli Bi, Wenqi Wang, Rui Li
Luteolin, a naturally occurring pharmaceutical compound with significant antitumor properties, faces challenges in clinical applications due to its low solubility in water and limited bioavailability. To address these issues, a one-step synthesis method was employed to encapsulate luteolin within ZIF-8. The successful preparation of luteolin@ ZIF-8 nanoparticles was confirmed through various analytical techniques, including fourier-transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM), laser size distribution analysis, X-ray diffraction (XRD), and release curve assessment...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38524525/extended-survival-with-metastatic-pancreatic-cancer-under-fruquintinib-treatment-after-failed-chemotherapy-two-case-reports
#40
Dan Wu, Qiong Wang, Shuai Yan, Xia Sun, Ya Qin, Ming Yuan, Nan-Yao Wang, Xian-Ting Huang
BACKGROUND: Pancreatic cancer is a highly malignant disease. After decades of treatment progress, the current five-year survival rate for patients is still less than 10%. For later-line treatment, the treatment options are even more limited. Anti-angiogenic drugs can improve progression-free survival in patients with advanced pancreatic cancer. Preclinical data show that fruquintinib might improve the prognosis of advanced pancreatic cancer by targeting angiogenesis and lymphopoiesis, improving the abnormal vascular structure, and modulating the tumour immune microenvironment...
March 6, 2024: World Journal of Clinical Cases
keyword
keyword
160416
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.